Microcap Ledger Intensity Therapeutics, Inc. $INTS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Shelton, CT
- Fiscal year end
- December 31
- Shares outstanding
- 3,264,879 [10-Q 2026-08-11]
What the company doesAI summary of filing
Intensity Therapeutics is a late-stage clinical biotechnology company developing INT230-6, a product candidate for treating solid tumors through direct intratumoral injection. INT230-6 combines two established chemotherapy drugs (cisplatin and vinblastine sulfate) with an amphiphilic molecule that enables the drugs to penetrate and disperse throughout tumors. The company is currently conducting Phase 3 testing in metastatic soft tissue sarcoma and Phase 2 testing in triple-negative breast cancer, with earlier-stage trials completed. Intensity is a pre-revenue, clinical-stage company funded through research collaborations and clinical development programs. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$5.44M | −$4.17M | $9.53M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$11.61M | −$9.23M | $11.92M | [10-K 2026-03-27] |
| FY ended Dec 2024 | — | −$16.27M | −$15.22M | $2.59M | [10-K 2026-03-27] |
- Quarterly cash burn
- −$2.08M
- Cash runway Estimate
- ~13.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 13,867,697 | [10-Q 2024-11-13] |
| 2025-03-12 | 15,180,945 | [10-K 2025-03-13] |
| 2025-05-12 | 18,398,202 | [10-Q 2025-05-13] |
| 2025-08-06 | 47,057,727 | [10-Q 2025-08-07] |
| 2025-11-05 | 60,064,965 | [10-Q 2025-11-06] |
| 2026-03-26 | 2,540,518 | [10-K 2026-03-27] |
| 2026-05-06 | 2,702,820 | [10-Q 2026-05-07] |
| 2026-08-07 | 3,264,879 | [10-Q 2026-08-11] |
- Shelf registration
- S-1 filed 2025-04-22; declared effective 2025-04-24 [S-1 2025-04-22]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-12-05. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-12-05 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-12-05] |
| 2025-06-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-06] |
| 2025-05-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-20] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | Wesolowski John M | grant | 3,688 | $3.48 | [4 2026-07-01] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-11 | 8-K | Results of operations |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-06-16 | 8-K | Shareholder vote results |
| 2026-05-07 | 8-K | Results of operations |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-03-27 | 8-K | Results of operations |
| 2026-03-27 | 10-K | Annual report |
| 2026-03-23 | 8-K | Other events |
| 2026-03-23 | 424B5 | Prospectus or prospectus supplement |
| 2026-03-06 | 8-K | Other events |
| 2026-03-05 | 8-K | Results of operations |
Alerts for $INTS
Email me when Intensity Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.